Cargando…

Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic

BACKGROUND: Sitagliptin is recommended for initial and maintenance dosing at 100 mg daily. Downward dose adjustment is recommended in patients with moderate or severe renal insufficiency. OBJECTIVES: To determine the prevalence of the potentially inappropriate initial dosing of sitagliptin based on...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarland, M. Shawn, Cross, L. Brian, Gross, Benjamin, Gentry, Chad, Tunney, Jeffrey, Patel, U. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438045/
https://www.ncbi.nlm.nih.gov/pubmed/19739879
http://dx.doi.org/10.18553/jmcp.2009.15.7.563
_version_ 1785092698116456448
author McFarland, M. Shawn
Cross, L. Brian
Gross, Benjamin
Gentry, Chad
Tunney, Jeffrey
Patel, U. P.
author_facet McFarland, M. Shawn
Cross, L. Brian
Gross, Benjamin
Gentry, Chad
Tunney, Jeffrey
Patel, U. P.
author_sort McFarland, M. Shawn
collection PubMed
description BACKGROUND: Sitagliptin is recommended for initial and maintenance dosing at 100 mg daily. Downward dose adjustment is recommended in patients with moderate or severe renal insufficiency. OBJECTIVES: To determine the prevalence of the potentially inappropriate initial dosing of sitagliptin based on estimated glomerular filtration rate (GFR) at baseline for pharmacist versus nonpharmacist prescribers in an internal medicine department of a private physician-owned multispecialty clinic that included a pharmacist-managed diabetes program. METHODS: This was a retrospective cross-sectional cohort analysis using data from an electronic medical record database of a private physician owned multispecialty clinic that included a pharmacist-managed diabetes program. For patients prescribed sitagliptin between October 17, 2006, and June 5, 2008, the variables of interest were (a) the initial sitagliptin dose; (b) the GFR, calculated for each patient using the 4-point Modification of Dosing in Renal Disease (MDRD) formula at the time of initiation of sitagliptin; and (c) whether the clinician initiating the dose was a pharmacist or nonpharmacist (i.e., internal medicine physician, nurse practitioner, or physician assistant). RESULTS: Of the 290 patients prescribed sitagliptin for the first time between October 17, 2006, and June 5, 2008, 35 (12.1%) received a potentially inappropriate initial dose according to product labeling regarding renal function; 21 were over-dosed and 14 were under-dosed. Potentially inappropriate dosing occurred in 1 of 158 patients (0.6%) who had initial dosing prescribed by a pharmacist compared with 34 of 132 patients (25.8%) for nonpharmacists (P less than 0.001, Fisher's exact test). CONCLUSIONS: Potentially inappropriate initial dosing of sitagliptin based on assessment of renal function was more likely to occur with nonpharmacist prescribers than with a pharmacist prescriber.
format Online
Article
Text
id pubmed-10438045
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104380452023-08-21 Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic McFarland, M. Shawn Cross, L. Brian Gross, Benjamin Gentry, Chad Tunney, Jeffrey Patel, U. P. J Manag Care Pharm Brief Communication BACKGROUND: Sitagliptin is recommended for initial and maintenance dosing at 100 mg daily. Downward dose adjustment is recommended in patients with moderate or severe renal insufficiency. OBJECTIVES: To determine the prevalence of the potentially inappropriate initial dosing of sitagliptin based on estimated glomerular filtration rate (GFR) at baseline for pharmacist versus nonpharmacist prescribers in an internal medicine department of a private physician-owned multispecialty clinic that included a pharmacist-managed diabetes program. METHODS: This was a retrospective cross-sectional cohort analysis using data from an electronic medical record database of a private physician owned multispecialty clinic that included a pharmacist-managed diabetes program. For patients prescribed sitagliptin between October 17, 2006, and June 5, 2008, the variables of interest were (a) the initial sitagliptin dose; (b) the GFR, calculated for each patient using the 4-point Modification of Dosing in Renal Disease (MDRD) formula at the time of initiation of sitagliptin; and (c) whether the clinician initiating the dose was a pharmacist or nonpharmacist (i.e., internal medicine physician, nurse practitioner, or physician assistant). RESULTS: Of the 290 patients prescribed sitagliptin for the first time between October 17, 2006, and June 5, 2008, 35 (12.1%) received a potentially inappropriate initial dose according to product labeling regarding renal function; 21 were over-dosed and 14 were under-dosed. Potentially inappropriate dosing occurred in 1 of 158 patients (0.6%) who had initial dosing prescribed by a pharmacist compared with 34 of 132 patients (25.8%) for nonpharmacists (P less than 0.001, Fisher's exact test). CONCLUSIONS: Potentially inappropriate initial dosing of sitagliptin based on assessment of renal function was more likely to occur with nonpharmacist prescribers than with a pharmacist prescriber. Academy of Managed Care Pharmacy 2009-09 /pmc/articles/PMC10438045/ /pubmed/19739879 http://dx.doi.org/10.18553/jmcp.2009.15.7.563 Text en Copyright © 2009, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Brief Communication
McFarland, M. Shawn
Cross, L. Brian
Gross, Benjamin
Gentry, Chad
Tunney, Jeffrey
Patel, U. P.
Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic
title Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic
title_full Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic
title_fullStr Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic
title_full_unstemmed Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic
title_short Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic
title_sort drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438045/
https://www.ncbi.nlm.nih.gov/pubmed/19739879
http://dx.doi.org/10.18553/jmcp.2009.15.7.563
work_keys_str_mv AT mcfarlandmshawn druguseevaluationofsitagliptindosingbypharmacistversusnonpharmacistcliniciansinaninternalmedicinedepartmentofaprivatephysicianownedmultispecialtyclinic
AT crosslbrian druguseevaluationofsitagliptindosingbypharmacistversusnonpharmacistcliniciansinaninternalmedicinedepartmentofaprivatephysicianownedmultispecialtyclinic
AT grossbenjamin druguseevaluationofsitagliptindosingbypharmacistversusnonpharmacistcliniciansinaninternalmedicinedepartmentofaprivatephysicianownedmultispecialtyclinic
AT gentrychad druguseevaluationofsitagliptindosingbypharmacistversusnonpharmacistcliniciansinaninternalmedicinedepartmentofaprivatephysicianownedmultispecialtyclinic
AT tunneyjeffrey druguseevaluationofsitagliptindosingbypharmacistversusnonpharmacistcliniciansinaninternalmedicinedepartmentofaprivatephysicianownedmultispecialtyclinic
AT patelup druguseevaluationofsitagliptindosingbypharmacistversusnonpharmacistcliniciansinaninternalmedicinedepartmentofaprivatephysicianownedmultispecialtyclinic